Drugmakers Tackle Biosimilars Oversight At FTC Forum

Law360, New York (February 4, 2014, 5:18 PM EST) -- Amgen Inc., Sandoz Inc. and other drugmakers locked horns Tuesday at a Federal Trade Commission forum examining state-level restrictions on pharmacy substitution of biosimilars and whether the copycat medicines should have distinct names, marking one of the highest-profile debates yet over the nascent field’s future.

The wrangling focused partly on legislation that’s been floated in at least 18 states — and enacted in at least four states — to regulate biosimilar access. The most controversial provisions require physician notification if a biosimilar is dispensed in place...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.